UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 3, 2022

KRYSTAL BIOTECH, INC.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation) 001-38210 (Commission File Number) 82-1080209 (IRS Employer Identification Number)

2100 Wharton Street, Suite 701 Pittsburgh, Pennsylvania 15203 (Address of principal executive offices, including Zip Code)

Registrant's telephone number, including area code: (412) 586-5830

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company \Box

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01 Regulation FD Disclosure.

On November 3, 2022, Krystal Biotech, Inc. (the "Company") presented new data entitled "Respiratory cell-type affinity and absolute *CFTR* expression in the primate airway upon nebulization of KB407" at the North American Cystic Fibrosis ("NACF") Conference in Philadelphia, PA. A copy of the presentation used at the NACF meeting is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The presentation will also be available on the "Investors" section of the Company's website at www.krystalbio.com.

This information in this Item 7.01 of this Current Report on Form 8-K and in Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing made by the Company pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit <u>No.</u>	Description
99.1	Presentation titled "Respiratory cell-type affinity and absolute CFTR expression in the primate airway upon nebulization of KB407"
104	Cover Page Interactive Data file (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 3, 2022

KRYSTAL BIOTECH, INC.

By: /s/ Kr Name: Krish Title: Chair

/s/ Krish S. Krishnan Krish S. Krishnan Chairman and Chief Executive Officer



Respiratory cell-type affinity and absolute *CFTR* expression in the primate airway upon nebulization of KB407

Trevor Parry, Sara Artusi, Jorge Guzman-Lepe, Mary Jane Duermeyer, Suma Krishnan Krystal Biotech, Inc.

Disclosures

T. Parry, S. Artusi, J. Guzman-Lepe, M. Duermeyer and S. Krishnan are employees of, and have equity interest in, Krystal Biotech, Inc.

XXX Krystal | 2

Cystic Fibrosis: Significant Unmet Need Despite Recent Approvals

Approximately 10% of CF patients have mutations that are not amenable to current small molecule approaches

Cystic Fibrosis

- Known as a life-threatening inherited disease, with an incidence of ~1/2,500 live births, affecting ~80,000 people worldwide 1
- It is autosomal recessive, caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR), leading to reduced and/or loss of CFTR function²⁻⁴
- Progressive lung disease is the primary cause of morbidity and mortality where the loss of CFTR-mediated chloride and bicarbonate transport leads to airway mucus obstruction, recurrent bacterial infection, and inflammation⁵

Unmet need remains significant despite recent approvals

- Small molecule correctors work by improving the functions of mutated CFTR; however, they only restore ~50% of protein function in patients with certain amenable mutations
- These therapies are ineffective in the ${\sim}10\%$ patients with mutations that do not produce any CFTR protein (null mutations)
- Suboptimal efficacy or tolerability issues remain even in those responsive to therapies



Estimated prevalence of cystic fibrosis per 100,000 habitants⁶

CF Prevalence & Incidence^{1,6,7}

- ~80,000 patients with CF worldwide
 - ~30,000 patients in US CF registry
 - ~1,000 new cases of CF diagnosed each year in the US

Middleton PG et al., NEJM 2019;381(19): 1809-1919; 2. O'Sullivan BP et al., Lancet 2009;373:1891-904; 3. Elborn JS et al., Lancet 2016; 388:2519-31; 4. Sanders DB et al., Pediatr Clin North Am 2016;63:567-84;
Stoltz DA et al., NEJM 2015; 372 (4): 351-362; 6. Lopes-Pacheco M, Front. Pharmacol. 2016; 7:275; 7. US Cystic Fibrosis Foundation.
CF, cystic Fibrosis.

KB407: A Differentiated Vector

An investigational inhaled gene therapy designed with the ability to redose

Herpes Simplex Virus Type 1 (HSV-1) as a Gene Delivery Platform

	HSV-1
In vivo dosing	Yes
Potential baseline neutralizing immunity	No
Repeat-dose capabilities	Yes
Carrying capacity	≥30 kb
Integrates payload into host cell DNA	No
Efficiency of delivering genetic cargo	High
Regulatory precedent	Yes

- HSV-1 is a well characterized virus, highly prevalent in the human population, with some estimates suggesting at least 67% of the US population ≥12 years have been exposed to HSV-1¹
- HSV-1 vectors efficiently transduce cells; their genomes remain episomal without integrating into host DNA^{2,3}, thus avoiding risks of insertional mutagenesis
- Additional benefit of the HSV-1 vectors include large payload capacities exceeding 30 kb and its natural property to resist immune clearance⁴⁻⁶


 Xu F, et al. J Infect Dis. 2002;185(8):1019–24; 2. Heldwein EE, Krummenacher C. Cell Mol Life Sci. 2008;65(11):1653-68; 3. Goins WF, et al., Engineering HSV-1 Vectors for Gene Therapy, in Herpes Simplex Virus: Methods and Protocols, J.R. Diefenbach and C. Fraefel, Editors. 2014, Springer New YorkNew York, NY, 65-79.4. Tognamell EI, et al. Front Infect Microbiol. 2019;9:127; 5. Yang L, et al. Front Immunol. 1954. https://doi.org/10.1016/j.2019;9:127; 5. Yang L, et al. Front Immunol. HSV-1, herpes animplex virus Yep 14.



- Based on Krystal's differentiated HSV-1 vector platform that has been clinically validated in a Phase 3 study in dystrophic epidermolysis bullosa (NCT04491604)
- Engineered to be replication defective with reduced cytotoxicity
- Encodes two full-length copies of human CFTR
- Duration of nebulization <30 minutes
- Episomal delivery of CFTR transgene does not disrupt host cell DNA
- Ability to redose and/or adjust dose over time as lung cells turnover

KB407 Corrected CFTR Defect in 3D Patient-Derived Intestinal Organoids

Restoration of normal cystic organoid morphology occurs irrespective of underlying CFTR mutation




- In healthy patient derived organoids (PDOs, top left), CFTR protein functions properly and enables water transport across the membrane leading to plump, round appearing PDOs
- In PDOs derived from CF patients (bottom left, center, and right), CFTR does not work properly and water is not transported causing PDOs to appear shrunken or shriveled
- Transduction by KB407 leads to a striking restoration of normal cystic organoid morphology even at the lowest MOI tested within 24 hours of transduction, irrespective of the underlying CFTR mutation
- KB407 also found to transduce primary CF patient derived small airway epithelial cells in a dose-dependent manner; the vector efficiently produces functional, full-length CFTR protein that properly traffics to the cell membrane

Freedman C, et al. Poster at the ASGCT 2020 Annual Meeting. Virtual. May 12-15, 2020. CF, cystic fibrosis; MOI, multiplicity of infection; PDOs, patient derived organoids.

Nebulized KB407 in Nonhuman Primates (NHPs)

Repeat doses of KB407 well tolerated and broadly distributed throughout lung tissue in NHPs



- No abnormal cage-side of clinical observations
- No changes in food consumption, bodyweight, or behavior during dosing period
- KB407 was distributed throughout airways, including the bronchioles and alveoli, with little-to-no vector detected in all other tissues
- All blood samples below the limit of detection for vector at all timepoints

Parry T, et al. Poster #541 at the 2021 North American Cystic Fibrosis Conference (NACFC). Virtual. November 1-5, 2021. NHPs, nonhuman primates.

XXX Krystal | 6

KB407 Repeat Dose (Weekly) GLP Toxicology Study in NHPs


Study Design

Group		Duration of Exposure (minutes)	Avg. Dose Deposited in Lungs (PFU/administration)	Dosing Days	Necropsy Days
Air	6	90		1, 8, 15	16
Vehicle	10	90		1, 8, 15	16, 43
Low Dose	10	18	1.81x10 ⁸ (male)	1, 8, 15	
KB407			2.33x10 ⁸ (female)		16, 43
High Dose KB407		.0 90	1.43x10 ⁹ (male)	1, 8, 15	16, 43
	10		2.11x10 ⁹ (female)		

Findings: NOAEL was determined to be the high dose

- No toxicity based on mortality, cage side/clinical observations, body weights, and clinical and anatomic pathology
- No changes in tidal volume, respiratory frequency, or minute volume at any dose level
- Mild mononuclear or mixed cell infiltrates in lungs and minimal to mild neutrophilic infiltration in nasal turbinates
- Effects were considered non-adverse due to the mild severity, lack of impact on health, and reversible on recovery

Parry T, et al. Poster #541 at the 2021 North American Cystic Fibrosis Conference (NACFC). Virtual. November 1-5, 2021. GLP, good laboratory practice; NHPs, nonhuman primates; NOAEL, no observed adverse effect level.




Fluorescent in situ hybridization

 Lung samples harvested 28 days after the last dose demonstrate persistence of the vector and CFTR expression


XXX Krystal | 7

Ciliated cells (AC-Tubulin⁺), 24-hours after last dose administered (Day 16 of GLP toxicology study)




Krystal | 8

Club cells (SCGB1A1⁺), 24-hours after last dose administered (Day 16 of GLP toxicology study)






Goblet cells (MUC5AC⁺), 24-hours after last dose administered (Day 16 of GLP toxicology study)



Krystal | 10


Macrophages (CD163⁺), 24-hours after last dose administered (Day 16 of GLP toxicology study)



GLP, good laboratory practice; NHP, nonhuman primate.


KB407 Expresses Human CFTR ≥ Endogenous CFTR in NHP Lungs

Absolute quantitation of exogenous human and endogenous NHP CFTR transcripts 48 hours post-KB407 nebulization



Assessment of Inflammatory Induction in Human CF Cells

No significant cytokine induction, even at MOI 10 and in presence of high levels of KB407-mediated CFTR expression, in CF colorectal epithelial cells 48 hours post-transduction



IL-10, IL-12p70, IP-10, GM-CSF, IFN-λ1/2/3 also assessed, no significant induction (data not shown) CF, cystic fibrosis: MOI, multiplicity of infection. Data Courtes of DF. Gerard Kalko, U. Newcaste.

Krystal | 13

Summary

~	Expression and localization of CFTR in CF primary small airway cells				
~	Post-translation glycosylation of CFTR protein				
~	Functional correction in 3D organoid model				
~	KB407 is stable after nebulization				
~	KB407 expresses human CFTR in airways of mice and NHPs upon nebulization				
~	No adverse findings in GLP toxicology study				
1	KB407 transduces ciliated and secretory cells (both club and goblet cells) in NHPs, suggesting that each cell type is amenable to KB407 transduction through their apical membranes upon nebulization				
~	Human <i>CFTR</i> transcripts found to be 106%-440% of the endogenous levels in NHPs upon KB407 administration, suggesting transgene expression at physiologically relevant levels				
~	No evidence of significant cytokine/chemokine induction in transduced CF patient cells, limiting likelihood of significant inflammation after KB407 nebulization in treated patients				
~	Investigational New Drug (IND) application accepted by FDA in July 2022				

CF, cystic fibrosis; GLP, good laboratory practice; NHPs, nonhuman primates.

Krystal | 14